Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome
Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome
About this item
Full title
Author / Creator
Cheng, Lan , Fu, Qianyu , Zhou, Longhua , Fan, Yuqin , Liu, Fenfen , Fan, Yuanyuan , Zhang, Xin , Lin, Weiqing and Wu, Xiaohe
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
The present study evaluated the effects of dapagliflozin, a SGLT2 inhibitor, or dapagliflozin plus metformin versus metformin monotherapy in patients with metabolic syndrome. This study included patients who admitted in Jiangxi Provincial People’s Hospital from January 1, 2017 to December 31, 2019 and were diagnosed with metabolic syndrome. A total...
Alternative Titles
Full title
Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_04b88455a13b4d9c9db8a6cf7dfd422c
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_04b88455a13b4d9c9db8a6cf7dfd422c
Other Identifiers
ISSN
2045-2322
E-ISSN
2045-2322
DOI
10.1038/s41598-021-03773-z
